Kamada Wins FDA Nod for High-Capacity San Antonio Plasma Center

Kamada ( (IL:KMDA) ) has issued an announcement.

On March 26, 2026, Kamada announced that the U.S. Food and Drug Administration approved its plasma collection center in San Antonio, Texas, following an on-site inspection in February 2026. The 11,100-square-foot facility, equipped with up to 50 donor beds, is cleared to begin commercial sales of normal source plasma and is designed to handle approximately 50,000 liters of plasma annually at full capacity.

The San Antonio center is structured to collect both normal source and specialty plasma, including anti-rabies and anti-D, positioning it to be among the largest specialty plasma collection sites in the U.S. Kamada expects this facility to contribute an estimated $8 million to $10 million in annual revenue at full utilization and to significantly enhance its overall plasma sourcing capacity alongside its existing Houston and Beaumont centers, strengthening its role in the plasma-derived therapies market.

The most recent analyst rating on (IL:KMDA) stock is a Buy with a ILs3049.00 price target. To see the full list of analyst forecasts on Kamada stock, see the IL:KMDA Stock Forecast page.

More about Kamada

Kamada Ltd. is a global biopharmaceutical company focused on specialty plasma-derived therapies for rare and serious conditions. Its portfolio includes multiple FDA-approved plasma-derived products, equine-based anti-snake venom treatments, and in-licensed drugs distributed in Israel and the MENA region, supported by three FDA-approved plasma collection centers in Texas.

Average Trading Volume: 84,513

Technical Sentiment Signal: Strong Buy

Current Market Cap: ILs1.47B

Find detailed analytics on KMDA stock on TipRanks’ Stock Analysis page.